flowchart LR
subgraph Sites["Clinical Sites"]
EHR[Electronic Health Records]
Wearables[Wearables & Sensors]
Patient[Patient Portal]
end
subgraph Core["Core Data Platforms"]
EDC[EDC<br/>Electronic Data Capture]
CTMS[CTMS<br/>Clinical Trial Management]
eTMF[eTMF<br/>Trial Master File]
RTSM[RTSM<br/>Randomization & Supply]
end
subgraph AI["AI Layer"]
Design[Protocol Design AI]
Recruit[Patient Matching AI]
QC[Data Quality AI]
Predict[Predictive Analytics]
end
subgraph Outputs["Regulatory & Insights"]
Submit[Regulatory Submissions]
Reports[Real-time Dashboards]
Risk[Risk Signals]
end
EHR -->|Patient Data| EDC
Wearables -->|Biometrics| EDC
Patient -->|ePRO/eCOA| EDC
EDC <--> CTMS
CTMS <--> eTMF
CTMS <--> RTSM
EDC --> QC
CTMS --> Predict
eTMF --> QC
Design --> EDC
Recruit --> CTMS
QC --> Reports
Predict --> Risk
eTMF --> Submit
EDC --> Submit
25 Clinical Trial IT Infrastructure
Clinical trials have undergone a fundamental transformation in how they capture, manage, and store data. What began as paper-based case report forms and filing cabinets has evolved into a layered digital infrastructure of interconnected platforms that power every stage of research: from site operations to regulatory submissions. This chapter examines the IT systems that form the transactional backbone of modern trials: Electronic Data Capture (EDC), Clinical Trial Management Systems (CTMS), electronic Trial Master Files (eTMF), and Randomization and Trial Supply Management (RTSM). It also covers the platform market dynamics shaping their evolution, and the regulatory framework (21 CFR Part 11, Annex 11, and ICH E6) that governs computerized systems in clinical research.
Understanding this infrastructure is essential for anyone involved in trial operations. The IT platforms determine what data can be captured and integrated, how operational metrics are tracked, and whether a trial is inspection-ready. They also provide the foundation on which the AI and automation tools discussed in Chapter 26 are built. Without validated, well-integrated core systems, advanced analytics and agentic automation have nothing reliable to operate on.
Throughout, we maintain a realistic perspective. Technology can reduce friction and surface risks earlier, but it requires validation, governance, and oversight to be defensible in an inspection. The goal is to help readers understand not only what systems exist, but how they interconnect and what regulatory requirements govern their use in clinical research.
25.1 The Modern Clinical Trial Ecosystem
The clinical trial technology stack has evolved from disconnected tools into an integrated ecosystem that powers every stage of research, from site operations to regulatory submissions. A decade ago, sponsors managed clinical data through a patchwork of vendor systems that rarely communicated: EDC databases that could not talk to randomization systems, trial master files stored in SharePoint folders with manual indexing, and clinical trial management systems that required spreadsheet reconciliation to produce accurate enrollment counts. Data flowed through exports, imports, and emails, a process that introduced latency, transcription errors, and audit risk at every handoff.
Today, the leading platforms aspire to unified architectures where patient data, operational metrics, essential documents, and supply chain signals flow through shared data models. In the best-integrated environments (particularly single-vendor platforms like Veeva Vault), when a site randomizes a patient, that event can propagate automatically: enrollment counts update in CTMS dashboards, treatment-specific CRF pages unlock in the EDC, drug shipment requests trigger in the supply management system, and expected document checklists populate in the eTMF. In practice, many sponsors still operate heterogeneous stacks with systems from multiple vendors, connected through middleware and custom integrations that require configuration, maintenance, and periodic reconciliation. The degree of integration varies widely across organizations, but the direction of travel is toward reduced manual handoffs and the shared data infrastructure on which analytics and automation depend.
The Technology Ecosystem
Figure 25.1 shows how the major systems interconnect.
The clinical trial technology stack consists of four interconnected core platforms, each serving a distinct but complementary function (Medidata Solutions 2024a).
Electronic Data Capture (EDC) is the primary tool for clinical data collection. EDC systems replace paper case report forms with validated electronic forms that capture patient data at the point of care. When a coordinator records a blood pressure reading, administers a questionnaire, or documents an adverse event, that data flows into the EDC. Modern EDC platforms include built-in edit checks that flag impossible values (a heart rate of 500?) or logical inconsistencies (an adverse event dated before the patient enrolled) in real-time, catching errors before they propagate. The EDC database ultimately becomes the foundation for regulatory submissions: every efficacy and safety analysis traces back to data captured here (U.S. Food and Drug Administration 2023).
Clinical Trial Management System (CTMS) is the operational command center. While EDC captures patient data, CTMS tracks trial operations: which sites are open, how many patients each has enrolled, when the next monitoring visit is scheduled, and what the budget burn rate looks like. CTMS provides the project management backbone that keeps a 50-site, 14-country trial from descending into chaos. It tracks milestones, manages contracts and payments, and generates the operational metrics that sponsors use to assess trial health (Grand View Research 2025).
Electronic Trial Master File (eTMF) is the regulatory archive. Every clinical trial generates thousands of documents: the protocol and its amendments, informed consent forms, IRB approvals, investigator CVs, monitoring reports, safety letters, and correspondence. Regulators require sponsors to maintain a complete Trial Master File as evidence that the trial was conducted properly. eTMF systems organize these documents according to the DIA Reference Model, track document completeness, and ensure inspection readiness (TMF Reference Model Initiative 2024). When an FDA inspector arrives, the eTMF is the first artifact they examine.
Randomization and Trial Supply Management (RTSM), sometimes called Interactive Response Technology (IRT), handles the logistics of treatment assignment and drug supply. When a patient is eligible for randomization, the RTSM system assigns them to a treatment arm according to the randomization scheme, maintaining the blind while ensuring balanced allocation. Simultaneously, RTSM tracks investigational product inventory at each site, triggers resupply shipments, and manages the complex logistics of getting the right drug to the right patient at the right time. For trials with temperature-sensitive biologics or personalized therapies, RTSM is mission-critical (Clinical Leader 2024).
These four systems do not operate in isolation: they exchange data continuously. When a patient is randomized in RTSM, that information flows to CTMS (updating enrollment counts) and EDC (enabling treatment-specific data collection). When a monitoring visit is completed, the report is filed in eTMF while the visit status updates in CTMS. This integration explains why unified platforms like Veeva Vault, which house all four systems in a single architecture, have gained such traction in the market (Veeva Systems 2024b).
25.2 The Foundational “Backbone”: Platform Wars
For decades, clinical data lived in silos: spreadsheets here, PDFs there, fax machines everywhere. Today, unified platforms serve as the operating system for clinical research. The clinical trial platform market is dominated by a handful of enterprise players (see Table 25.1), with intense competition driving innovation (Medidata Solutions 2024a):
| Vendor | Primary Strengths | Market Position | Cloud Model | AI Capabilities |
|---|---|---|---|---|
| Medidata (Dassault) | Industry-standard EDC (Rave), 25-year track record, 38,000+ studies | Market leader in EDC | Cloud/SaaS | AI-powered signal detection, synthetic control arms |
| Veeva Systems | Unified Vault platform (eTMF, CTMS, EDC), life sciences focus | Fast-growing challenger | Cloud-native | TMF Intake Agent, Quality Check Agent |
| Oracle | Enterprise scale, Siebel Clinical One, regulatory expertise | Established incumbent | Cloud/On-prem | ML-based safety analytics |
| IQVIA | Real-world data integration, global CRO services | CRO-integrated platform | Cloud/SaaS | Intelligent eTMF, predictive enrollment |
TipDeployment Trends
Over 57% of new clinical trial system deployments are now cloud-based, up from 30% five years ago (International Data Corporation 2024). The pandemic accelerated this shift.
Major Platform Vendors
Medidata (acquired by Dassault Systemes in 2019) remains the dominant EDC platform, with its Rave EDC system recognized as the industry standard. The 2025 ISR Benchmarking Report ranked Rave EDC as the top-preferred EDC system based on independent sponsor evaluations. Medidata’s scale is substantial: over 700,000 certified site users, 1.8 million EDC users, and more than 38,000 studies managed across all phases and therapeutic areas (Medidata Solutions 2024b).
Medidata’s AI capabilities include Acorn AI, which provides synthetic control arms using historical patient data to reduce or eliminate placebo groups in certain trial designs. Their Sensor Cloud integrates wearable device data directly into the EDC, enabling continuous physiological monitoring without manual data entry.
Veeva has rapidly gained market share by offering a unified Vault platform that integrates eTMF, CTMS, and EDC in a single system, in contrast to Medidata’s historically modular approach. Veeva serves only life sciences, unlike Oracle or Salesforce, which operate across multiple industries; this concentration has shaped a platform built around clinical and regulatory workflows rather than adapted from general-purpose enterprise software. Beyond its core platform, Veeva is deploying specialized AI Agents that automate the most tedious parts of clinical operations. Figure 25.2 illustrates the document processing workflow:
sequenceDiagram
participant Site as Site Upload
participant Intake as TMF Intake Agent
participant QC as Quality Check Agent
participant TMF as eTMF Vault
participant User as Document Manager
Site->>Intake: Upload document (PDF/scan)
Intake->>Intake: Extract metadata<br/>(investigator, date, type)
Intake->>Intake: Classify to DIA artifact
Intake->>QC: Route for quality check
QC->>QC: Check for signatures
QC->>QC: Validate completeness
alt Document Complete
QC->>TMF: File to correct binder
TMF->>User: Notification: "Document filed"
else Issues Found
QC->>User: Alert: "Missing signature"
User->>Site: Request correction
end
Veeva’s AI capabilities center on two key agents. The TMF Intake Agent automatically classifies documents uploaded by sites, extracting metadata such as investigator name and document date to route files to the correct TMF binder. The Quality Check Agent reviews documents for errors (missing signatures, wrong versions, incomplete forms) before a human ever sees them, reducing TMF migration prep time by over 80% according to Veeva’s published benchmarks (Veeva Systems 2024a).
The eTMF market alone is worth $1.4 billion and growing at 12.8% annually (MarketsandMarkets 2024). Table 25.2 compares the three vendors competing for dominance:
| Feature | Veeva eTMF | IQVIA eTMF | Phlexglobal eTMF |
|---|---|---|---|
| Auto-Classification | AI-powered DIA mapping | ML-based indexing | Intelligent auto-filing |
| Completeness Prediction | Expected document lists | Milestone-based gaps | Risk-based prioritization |
| Inspection Readiness | Real-time dashboards | Inspection-ready reports | Audit trail analytics |
| Site Integration | SiteVault connected | Site-facing portal | Sponsor-site bridge |
| Unique Strength | Unified Vault ecosystem | RWD integration | eTMF-specialist focus |
These platforms use AI in two ways. First, auto-indexing uses machine learning models to classify unorganized scans into the DIA Reference Model structure. Second, completeness prediction algorithms identify missing documents based on study milestones, for example flagging that “Site 101 has initialized but is missing a financial disclosure form” (IQVIA 2024; Phlexglobal 2024).
Medable took a different path: its platform was designed for the decentralized trial from the outset. As hybrid and virtual trials became mainstream, Medable’s modular platform enables patients to participate from home (see Table 25.3) (Medable 2024a):
| Capability | What It Does | Impact |
|---|---|---|
| TeleVisit | Video conferencing for remote assessments | Reduced travel for suitable protocols (implementation-dependent) |
| eConsent | Multimedia-rich digital consent | Improved comprehension and workflow consistency (context-dependent) |
| Medable AI | Generates digital eCOA from paper protocols | Faster digitization and reuse of instruments (vendor-reported) |
| TMF Automation | Processes DCT-generated document flood | Helps manage higher document volume (protocol-dependent) |
25.3 Regulatory Framework for Computerized Systems
For any sponsor or CRO deploying computerized systems in clinical trials (whether traditional platforms or AI-enabled tools), understanding the regulatory landscape is essential. This section provides a practical framework for determining what validation, documentation, and oversight are required, and how the regulatory hierarchy applies to clinical trial technology.
Enforceable Standards vs. Recommendations
A critical distinction exists between enforceable legal requirements and regulatory guidance, as summarized in Table 25.4. Failure to comply with enforceable requirements can result in warning letters, clinical holds, or rejection of submissions. Guidance documents represent FDA or EMA “current thinking” and are recommendations, not mandates, though departing from them without justification invites scrutiny.
| Category | Examples | Consequence of Non-Compliance |
|---|---|---|
| Enforceable Law/Regulation | 21 CFR Part 11 (electronic records), 21 CFR Part 312 (INDs), ICH E6 GCP, EU Clinical Trials Regulation | Warning letters, clinical holds, application rejection, criminal liability |
| Enforceable GxP Standards | ICH E6(R3) computerized systems requirements, Annex 11 (EU), data integrity requirements | Inspection findings, Form 483 observations, regulatory action |
| Regulatory Guidance | FDA draft guidance on AI for regulatory decisions (Jan 2025), EMA reflection paper on AI (Sept 2024) | Increased scrutiny, requests for additional information, delays |
Validation and Documentation Requirements
AI systems and computerized systems used in clinical trials must meet the same validation requirements as any other regulated software (see Table 25.5). The applicable standards depend on the regulatory jurisdiction and the system’s role.
21 CFR Part 11 (FDA) and Annex 11 (EU) Requirements:
Both frameworks require that computerized systems generating, modifying, or storing electronic records for regulatory submissions meet validation and control standards:
- System validation: Documented evidence that software performs as intended, including AI model verification
- Audit trails: Computer-generated, time-stamped trails recording all system actions that create, modify, or delete electronic records
- Access controls: Unique user identification, authentication, and role-based permissions
- Data integrity: Controls ensuring data is attributable, legible, contemporaneous, original, and accurate (ALCOA)
- Operational controls: Documented procedures for system use, maintenance, and change control
ICH E6(R3) Computerized Systems Requirements (January 2025):
The updated GCP guideline adds specific requirements relevant to AI:
- Fitness-for-purpose: Systems must be validated to be fit for the specific use in the trial
- Data governance: Dedicated section requiring documented data and records management
- Risk-based validation: Proportional approach based on impact on patient safety and data reliability
- Metadata and automated sources: Recognition of data from wearables, sensors, and automated systems as primary source data
| Requirement | 21 CFR Part 11 | Annex 11 | ICH E6(R3) |
|---|---|---|---|
| System validation | Required | Required | Required (risk-based) |
| Audit trails | Required | Required | Required |
| Access controls | Required | Required | Required |
| Change control | Required | Required | Required |
| Data backup/recovery | Required | Required | Required |
| Training documentation | Required | Required | Required |
| Supplier qualification | N/A | Required | Required |